Ovarian cancer surgery: Difference between revisions

Jump to navigation Jump to search
(Mahshid)
Line 7: Line 7:
==Surgical Therapy==
==Surgical Therapy==


Early-Stage Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer


Early-Stage Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment
* If the [[tumor]] is well differentiated or moderately well differentiated, [[surgery]] alone may be adequate treatment for patients with stage IA and IB disease.
Treatment options:
* Surgery should include [[hysterectomy]], [[bilateral]] [[salpingo-oophorectomy]], and omentectomy. Additionally, the undersurface of the [[diaphragm]] should be visualized and biopsied
* [[Pelvic]] and [[abdominal]] [[peritoneal]] [[biopsies]] and [[pelvic]] and [[Paraaortic lymph nodes|paraaortic lymph node]] biopsies are required and [[peritoneal]] washings should be obtained routinely.
* In selected patients who desire childbearing and have grade I [[tumors]], unilateral [[salpingo-oophorectomy]] may be associated with a low risk of recurrence.


If the tumor is well differentiated or moderately well differentiated, surgery alone may be adequate treatment for patients with stage IA and IB disease. Surgery should include hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. Additionally, the undersurface of the diaphragm should be visualized and biopsied; pelvic and abdominal peritoneal biopsies and pelvic and para-aortic lymph node biopsies are required and peritoneal washings should be obtained routinely. In selected patients who desire childbearing and have grade I tumors, unilateral salpingo-oophorectomy may be associated with a low risk of recurrence.
Primary surgical cytoreduction


Primary surgical cytoreduction
* Patients diagnosed with stage III and stage IV disease are treated with [[surgery]] and [[chemotherapy]]; however, the outcome is generally less favorable for patients with stage IV disease.
* The role of surgery for patients with stage IV disease is unclear, but in most instances, the bulk of the disease is [[Intra-abdominal|intra-abdominal,]] and surgical procedures similar to those used in the management of patients with stage III disease are applied.
* The options for [[intraperitoneal]] (IP) regimens are also less likely to apply both practically (as far as inserting an IP catheter at the outset) and theoretically (aimed at destroying [[microscopic]] disease in the [[peritoneal cavity]]) in patients with stage IV disease.


Patients diagnosed with stage III and stage IV disease are treated with surgery and chemotherapy; however, the outcome is generally less favorable for patients with stage IV disease. The role of surgery for patients with stage IV disease is unclear, but in most instances, the bulk of the disease is intra-abdominal, and surgical procedures similar to those used in the management of patients with stage III disease are applied. The options for intraperitoneal (IP) regimens are also less likely to apply both practically (as far as inserting an IP catheter at the outset) and theoretically (aimed at destroying microscopic disease in the peritoneal cavity) in patients with stage IV disease.
Advanced-Stage Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer


Advanced-Stage Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment
* [[Surgery]] has been used as a therapeutic modality and also to adequately stage the disease.  
Surgery has been used as a therapeutic modality and also to adequately stage the disease. Surgery should include total abdominal hysterectomy and bilateral salpingo-oophorectomy with omentectomy and debulking of as much gross tumor as can safely be performed. While primary cytoreductive surgery may not correct for biologic characteristics of the tumor, considerable evidence indicates that the volume of disease left at the completion of the primary surgical procedure is related to patient survival.
* [[Surgery]] should include total [[abdominal]] [[hysterectomy]] and [[bilateral]] [[salpingo-oophorectomy]] with omentectomy and [[debulking]] of as much gross [[tumor]] as can safely be performed. While primary cytoreductive surgery may not correct for [[biologic]] characteristics of the [[tumor]], considerable evidence indicates that the volume of disease left at the completion of the primary surgical procedure is related to patient survival.


Adjuvant Therapy
Adjuvant Therapy


For patients unable to undergo surgery, or for those with greater than 1 cm residual disease following surgery, IV chemotherapy is the standard. The foundation is the platinum agents: cisplatin, or its second-generation analog, carboplatin, given either alone or in combination with other drugs.
* For patients unable to undergo surgery, or for those with greater than 1 cm residual disease following surgery, IV [[chemotherapy]] is the standard.  
* The foundation is the [[platinum]] agents: [[cisplatin]], or its second-generation analog, [[carboplatin]], given either alone or in combination with other drugs.


==References==
==References==

Revision as of 13:21, 11 July 2019

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer surgery

CDC on Ovarian cancer surgery

Ovarian cancer surgery in the news

Blogs on Ovarian cancer surgery

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Surgery is the preferred treatment and is frequently necessary to obtain a tissue specimen for differential diagnosis via its histology. Surgery performed by a specialist in gynecologic oncology usually results in an improved result. Improved survival is attributed to more accurate staging of the disease and a higher rate of aggressive surgical excision of tumor in the abdomen by gynecologic oncologists as opposed to general gynecologists and general surgeons.

Surgical Therapy

Early-Stage Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer

Primary surgical cytoreduction

  • Patients diagnosed with stage III and stage IV disease are treated with surgery and chemotherapy; however, the outcome is generally less favorable for patients with stage IV disease.
  • The role of surgery for patients with stage IV disease is unclear, but in most instances, the bulk of the disease is intra-abdominal, and surgical procedures similar to those used in the management of patients with stage III disease are applied.
  • The options for intraperitoneal (IP) regimens are also less likely to apply both practically (as far as inserting an IP catheter at the outset) and theoretically (aimed at destroying microscopic disease in the peritoneal cavity) in patients with stage IV disease.

Advanced-Stage Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer

  • Surgery has been used as a therapeutic modality and also to adequately stage the disease.
  • Surgery should include total abdominal hysterectomy and bilateral salpingo-oophorectomy with omentectomy and debulking of as much gross tumor as can safely be performed. While primary cytoreductive surgery may not correct for biologic characteristics of the tumor, considerable evidence indicates that the volume of disease left at the completion of the primary surgical procedure is related to patient survival.

Adjuvant Therapy

  • For patients unable to undergo surgery, or for those with greater than 1 cm residual disease following surgery, IV chemotherapy is the standard.
  • The foundation is the platinum agents: cisplatin, or its second-generation analog, carboplatin, given either alone or in combination with other drugs.

References


Template:WikiDoc Sources